since the response rate of 19 % ( 95 % confidence limits , 8 % -38 % ) is similar to that noted for dacarbazine , carboplatin , singly and in combination with other agents , needs further evaluation in patients with malignant melanoma .
C0010927
dacarbazine
C0025202
malignant melanoma